EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Adjuvant Radiotherapy After Radical Cystectomy for Muscle-invasive Bladder Cancer: A Phase 2 Trial—Results of Secondary Endpoints

Flor Verghote, Elke Rammant, Piet Dirix, Charles Van Praet, Charlien Berghen, Sara Junius, Nick Liefhooghe, Leen Noé, Piet Ost, Karel Decaestecker, Geert Villeirs, Alexander Decruyenaere und 4 weitere

European Urology Focus · 2025

DOI: 10.1016/j.euf.2025.02.005 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Urology Focus, 2025. Verfasst von Flor Verghote und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation-Oncology, Ghent University Hospital, Ghent, Belgium; Department of Human structure and Repair, Ghent University, Ghent, Belgi…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cystectomy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kom op tegen kanker, Novartis, Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Patients with muscle-invasive bladder cancer (MIBC) who develop a recurrence after radical cystectomy (RC) have poor outcomes. This study aims to evaluate the safety and efficacy of adjuvant radiotherapy (ART) in mitigating pelvic recurrences in high-risk MIBC patients. We report on survival outcomes, health-related quality of life (HRQoL), and hematological toxicity for these patients. METHODS: A multicentric phase 2 trial was conducted from August 2014 to October 2020, in which 72 high-risk MIBC patients received ART after RC. High risk was defined by the presence of one or more of the following criteria: pT3 stage and lymphovascular invasion, pT4 stage, fewer than ten lymph nodes removed, positive lymph nodes, and positive surgical margins. Using intensity-modulated radiotherapy, patients with pelvic lymph nodes ± cystectomy bed (in case of a positive surgical margin) received 50 Gy in 25 fractions. Outcomes were local relapse-free rate (LRFR), clinical relapse-free survival (CRFS), overall survival (OS) (Kaplan-Meier statistics), HRQoL (European Organisation for Research and Treatment of Cancer QLQ-C30/QLQ-BLM30 surveys), and hematological toxicity (Common Terminology Criteria for Adverse Events grading). KEY FINDINGS AND LIMITATIONS: The median follow-up of patients without a recurrence was 39 mo. At 2 and 5 yr, LRFRs were 81% (95% confidence interval [CI] 71-91%) and 79% (95% CI 68-89%), CRFS rates were 32% (95% CI 21-42%) and 20% (95% CI 11-30%), and OS rates were 48% (95% CI 36-59%) and 34% (95% CI 22-45%), respectively. At the end of ART, several symptoms worsened, most returning to baseline within the first few months. Diarrhea showed the greatest deterioration, recovering to baseline score only partially. Hematological toxicity of incidence grade ≥2 included lymphopenia (75%), neutropenia (2%), thrombopenia (2%), and anemia (17%). Limitations include the single-arm design and the limited availability of blood samples and surveys. CONCLUSIONS AND CLINICAL IMPLICATIONS: ART after RC is well tolerated and leads to a favorable local control rate, supporting its use in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCystectomyHumansMaleFemaleAgedRadiotherapy, AdjuvantNeoplasm InvasivenessMiddle AgedQuality of LifeNeoplasm Recurrence, LocalAged, 80 and over

Stichwörter der Autor:innen

Health-related quality of lifeLocal controlMuscle-invasive bladder cancerOutcomeRadiotherapyToxicityUrothelial cancer

Autor:innen und Institutionen

  • Department of Radiation-Oncology, Ghent University Hospital, Ghent, Belgium; Department of Human structure and Repair, Ghent University, Ghent, Belgium. Electronic address: flor.verghote@uzgent.be.
  • Department of Radiation-Oncology, Ghent University Hospital, Ghent, Belgium; Department of Human structure and Repair, Ghent University, Ghent, Belgium.
  • Department of Radiation-Oncology, Iridium Network, Antwerp, Belgium.
  • Department of Urology, Ghent University Hospital (ERN eUROGEN accredited center), Ghent, Belgium.
  • Department of Radiation-Oncology, University Hospitals Leuven, Leuven, Belgium.
  • Department of Radiation-Oncology, CH-M/AMPR, Mouscron, Belgium.

Förderung

  • Kom op tegen kanker
  • Novartis
  • Bayer

Zitieren

APA

Verghote, F., Rammant, E., Dirix, P., Van Praet, C., Berghen, C., Junius, S., Liefhooghe, N., Noé, L., Ost, P., Decaestecker, K., Villeirs, G., Decruyenaere, A., De Man, K., Verbeke, S., De Maeseneer, D., & Fonteyne, V. (2025). Adjuvant Radiotherapy After Radical Cystectomy for Muscle-invasive Bladder Cancer: A Phase 2 Trial—Results of Secondary Endpoints. European Urology Focus. https://doi.org/10.1016/j.euf.2025.02.005

Vancouver

Verghote F, Rammant E, Dirix P, Van Praet C, Berghen C, Junius S, et al. Adjuvant Radiotherapy After Radical Cystectomy for Muscle-invasive Bladder Cancer: A Phase 2 Trial—Results of Secondary Endpoints. European Urology Focus. 2025. doi:10.1016/j.euf.2025.02.005

BibTeX
@article{Verghote2025,
  author = {Verghote, Flor and Rammant, Elke and Dirix, Piet and Van Praet, Charles and Berghen, Charlien and Junius, Sara and Liefhooghe, Nick and Noé, Leen and Ost, Piet and Decaestecker, Karel and Villeirs, Geert and Decruyenaere, Alexander and De Man, Kathia and Verbeke, Sofie and De Maeseneer, Daan and Fonteyne, Valérie},
  title = {Adjuvant Radiotherapy After Radical Cystectomy for Muscle-invasive Bladder Cancer: A Phase 2 Trial—Results of Secondary Endpoints},
  journal = {European Urology Focus},
  year = {2025},
  doi = {10.1016/j.euf.2025.02.005}
}
Kostenlos starten →